Journal of the American Geriatrics Society,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 28, 2024
Abstract
Background
People
with
chronic
kidney
disease
(CKD)
have
an
elevated
risk
of
cognitive
impairment
(CI).
Medications
anticholinergic
activity
are
recognized
for
their
adverse
reactions
on
central
nervous
system.
The
putative
association
between
the
burden
and
CI
has
not
previously
been
evaluated
in
patients
CKD.
study
aimed
to
(i)
describe
prescriptions
medications
activity,
(ii)
analyze
factors
associated
these
prescriptions,
(iii)
evaluate
burden's
performance.
Methods
CKD‐REIN,
a
prospective
cohort
study,
enrolled
nephrology
outpatients
confirmed
diagnosis
CKD
(eGFR
<60
mL/min/1.73m
2
).
Drug
were
recorded
prospectively
during
5‐year
follow‐up.
Mini
Mental
State
Examination
(MMSE)
was
assessed
at
baseline
defined
as
MMSE
score
<24/30.
For
each
patient,
determined
by
summing
Anticholinergic
Cognitive
Burden
(ACB)
scores
all
prescription
drugs
baseline.
Multinomial
logistic
regression
used
ACB
score.
Logistic
Results
At
baseline,
3007
(median
age
[IQR],
69[60–76];
65%
men)
had
data
included.
1549
(52%)
taking
least
one
drug
properties.
Most
(1092;
70%)
low
burden,
294
(19%)
moderate
163
(11%)
high
burden.
A
history
neurological/psychiatric
disorders
higher
number
daily
greater
probability
having
(odds
ratio
(OR)
[95%
confidence
interval
(95%
CI)]
=
1.88[1.29;2.74]
1.53[1.45;1.61],
respectively).
Patients
significantly
presenting
impairment,
compared
without
(OR[95%
CI]
1.76[1.12;2.75])
after
adjustment
sociodemographic
factors,
comorbidities,
laboratory
data,
taken
daily.
Conclusions
results
our
emphasize
need
caution
properties
BJPsych Open,
Journal Year:
2024,
Volume and Issue:
10(5)
Published: Sept. 1, 2024
Background
Medications
with
anticholinergic
properties
are
associated
a
range
of
adverse
effects
that
tend
to
be
worse
in
older
people.
Aims
To
investigate
medication
regimens
high
burden,
prescribed
for
adults
under
the
care
mental
health
services.
Method
Clinical
audit
prescribing
practice,
using
standardised
data
collection
tool.
Results
Fifty-seven
trusts/healthcare
organisations
submitted
on
medicines
7915
patients:
two-thirds
(66%)
were
properties,
while
just
quarter
(23%)
had
regimen
burden
(total
score
≥3
effect
cognition
(AEC)
scale).
Some
16%
patients
diagnosis
dementia
or
mild
cognitive
impairment
compared
35%
those
without
such
diagnoses.
A
was
mostly
because
combinations
commonly
psychotropic
medications,
principally
antidepressant
and
antipsychotic
medications
individual
AEC
scores
1
2.
Conclusions
Adults
people's
services
multiple
psychiatric
physical
disorders;
these
can
have
often
an
inadvertent
consequence
co-prescription
modest
activity.
Prescribers
should
assess
regimens,
assiduously
check
consider
alternative
less
where
indicated.
The
use
scale,
as
AEC,
which
identifies
level
central
activity
relevant
helpful
clinical
guide.
Expert Opinion on Drug Safety,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 7
Published: Aug. 6, 2024
Considering
the
vulnerability
of
older
adults
to
adverse
drug
reactions,
medications
with
strong
anticholinergic
properties
are
considered
potentially
inappropriate
for
this
population.
This
study
aims
characterize
adults'
profile
anticholinergics
use
and
identify
factors
associated
their
use.
Basic & Clinical Pharmacology & Toxicology,
Journal Year:
2024,
Volume and Issue:
135(4), P. 451 - 463
Published: Sept. 1, 2024
Abstract
Several
medications
are
commonly
administered
to
older
Japanese
patients.
Since
some
of
them
have
not
been
included
in
previously
developed
scales
estimate
the
anticholinergic
burden,
we
a
new
muscarinic
receptor
binding‐based
burden
scale.
This
study
aimed
investigate
functional
inhibitory
effects
60
medications,
classified
as
3
and
2
by
scale,
on
receptor‐mediated
contractions
bladder
ileum.
The
relaxation
response
induced
these
drugs
isolated
rat
bladders
ileum
smooth
muscles
constricted
carbachol
was
assessed
using
organ
bath
method.
All
inhibited
muscle
contractile
responses
activation
concentration‐dependent
manner
Notably,
variations
were
observed
drugs,
function
EC
50
values
positively
correlated
with
binding
IC
results
this
provide
pharmacological
evidence
for
Implementation
scale
may
help
reduce
risk
constipation
urinary
retention,
which
common
side
associated
drugs.
Journal of the American Geriatrics Society,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 28, 2024
Abstract
Background
People
with
chronic
kidney
disease
(CKD)
have
an
elevated
risk
of
cognitive
impairment
(CI).
Medications
anticholinergic
activity
are
recognized
for
their
adverse
reactions
on
central
nervous
system.
The
putative
association
between
the
burden
and
CI
has
not
previously
been
evaluated
in
patients
CKD.
study
aimed
to
(i)
describe
prescriptions
medications
activity,
(ii)
analyze
factors
associated
these
prescriptions,
(iii)
evaluate
burden's
performance.
Methods
CKD‐REIN,
a
prospective
cohort
study,
enrolled
nephrology
outpatients
confirmed
diagnosis
CKD
(eGFR
<60
mL/min/1.73m
2
).
Drug
were
recorded
prospectively
during
5‐year
follow‐up.
Mini
Mental
State
Examination
(MMSE)
was
assessed
at
baseline
defined
as
MMSE
score
<24/30.
For
each
patient,
determined
by
summing
Anticholinergic
Cognitive
Burden
(ACB)
scores
all
prescription
drugs
baseline.
Multinomial
logistic
regression
used
ACB
score.
Logistic
Results
At
baseline,
3007
(median
age
[IQR],
69[60–76];
65%
men)
had
data
included.
1549
(52%)
taking
least
one
drug
properties.
Most
(1092;
70%)
low
burden,
294
(19%)
moderate
163
(11%)
high
burden.
A
history
neurological/psychiatric
disorders
higher
number
daily
greater
probability
having
(odds
ratio
(OR)
[95%
confidence
interval
(95%
CI)]
=
1.88[1.29;2.74]
1.53[1.45;1.61],
respectively).
Patients
significantly
presenting
impairment,
compared
without
(OR[95%
CI]
1.76[1.12;2.75])
after
adjustment
sociodemographic
factors,
comorbidities,
laboratory
data,
taken
daily.
Conclusions
results
our
emphasize
need
caution
properties
